{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Rigosertib sodiumCAS：592542-60-4
Molecular Formula：C21H24NNaO8S
Molecular Weight：473.47
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 592542-60-4 |
| Name | Rigosertib sodium |
| Molecular Formula | C21H24NNaO8S |
| Molecular Weight | 473.47 |
| Solubility | Soluble in DMSO ≥15mg/mL;Soluble in Water ≥5mg/mL |
| Purity | ≥98% |
| Appearance | White to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| Target Point | Polo-like Kinase (PLK) |
| Passage | Cell Cycle |
| Background | Rigosertib sodium is a selective non-ATP-competitive PLK1 inhibitor. |
| Biological Activity | Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent， which induces apoptosis by inhibition the PI3K/Akt pathway， promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM.[1-5] |
| Data Literature Source | [1]. Xu F， et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signalingtransduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014 Dec 4;4:7310. [2]. Hyoda T， et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci. 2015 Mar;106(3):287-93. [3]. Gumireddy K， et al. ON01910， a non-ATP-competitive small molecule inhibitor of Plk1， is a potent anticancer agent. Cancer Cell. 2005 Mar;7(3):275-86. [4]. Reddy MV， et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2，4，6-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis， structure-activity relationship， and biological activity. J Med Chem. [5]. Chapman CM， et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res. 2012 Apr 1;18(7):1979-91 |
| Unit | Bottle |
| Specification | 1mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no experimental images.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
